The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M. Stein, Martin S. Tallman, Guillermo Garcia‐Manero et al.|Blood|2018Cited by 457
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialPhilippe Armand, Leo I. Gordon, Arnon Nagler et al.|Journal of Clinical Oncology|2013Cited by 439
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, William A. Wood, John Edwards et al.|Blood|2017Cited by 296
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug SensitivityKevin Lin, Kris C. Wood, Abigail Xie et al.|Cell Metabolism|2019Cited by 112
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A. Rizzieri, Gautam Borthakur, Sarah Cooley et al.|Leukemia & lymphoma/Leukemia and lymphoma|2016Cited by 78